EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Safety and Glycemic Outcomes During the MiniMed TM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes

Catherine Pihoker, Dorothy I Shulman, Gregory P Forlenza iD, Kevin B Kaiserman, Jennifer L Sherr iD, James R Thrasher, Bruce A Buckingham, Mark S Kipnes, Bruce W Bode, Anders L Carlson, Scott W Lee, Kashif Latif und 14 weitere

Diabetes Technology & Therapeutics · 2023-11 · 25 (11) · 755-764

DOI: 10.1089/dia.2023.0255 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 07.11.2023. Verfasst von Catherine Pihoker und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis, Hypoglycemia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

During MiniMed™ advanced hybrid closed-loop (AHCL) use by adolescents and adults in the pivotal trial, glycated hemoglobin (A1C) was significantly reduced, time spent in range (TIR) was significantly increased, and there were no episodes of severe hypoglycemia or diabetic ketoacidosis (DKA). The present study investigated the same primary safety and effectiveness endpoints during AHCL use by a younger cohort with type 1 diabetes (T1D).

Methods

An intention-to-treat population ( N = 160, aged 7–17 years) with T1D was enrolled in a single-arm study at 13 investigational centers. There was a run-in period (∼25 days) using HCL or sensor-augmented pump with/without predictive low-glucose management, followed by a 3-month study period with AHCL activated at two glucose targets (GTs; 100 and 120 mg/dL) for ∼45 days each. The mean ± standard deviation values of A1C, TIR, mean sensor glucose (SG), coefficient of variation (CV) of SG, time at SG ranges, and insulin delivered between run-in and study were analyzed (Wilcoxon signed-rank test or t -test).

Results

Compared with baseline, AHCL use was associated with reduced A1C from 7.9 ± 0.9% ( N = 160) to 7.4 ± 0.7% ( N = 136) ( P < 0.001) and overall TIR increased from the run-in 59.4 ± 11.8% to 70.3 ± 6.5% by end of study ( P < 0.001), without change in CV, time spent below range (TBR)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetic KetoacidosisHypoglycemiaAdolescentAdultChildHumansBlood GlucoseBlood Glucose Self-MonitoringGlucoseGlycated HemoglobinHypoglycemic AgentsInsulinInsulin Infusion SystemsTreatment Outcome

Stichwörter der Autor:innen

A1CActive insulin timeAdvanced hybrid closed loopGlucose targetPediatricTime-in-rangeType 1 diabetes

Substanzen

Blood GlucoseGlucoseGlycated HemoglobinHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Pediatrics, University of Washington, Seattle, Washington, USA.
  • University of South Florida, Pediatric Diabetes and Endocrinology, Tampa, Florida, USA.
  • Department of Pediatrics, Barbara Davis Center of Childhood Diabetes, Aurora, Colorado, USA.
  • SoCal Diabetes, Torrance, California, USA.
  • Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Arkansas Diabetes and Endocrinology Center, Little Rock, Arkansas, USA.

ORCID-Profile: Gregory P Forlenza, Jennifer L Sherr, Toni L Cordero, Robert A Vigersky

Zitieren

APA

Pihoker, C., Shulman, D. I., Forlenza, G. P., Kaiserman, K. B., Sherr, J. L., Thrasher, J. R., Buckingham, B. A., Kipnes, M. S., Bode, B. W., Carlson, A. L., Lee, S. W., Latif, K., Liljenquist, D. R., Slover, R. H., Dai, Z., Niu, F., Shin, J., Jonkers, R. A. M., Roy, A., …, & MiniMed AHCL Study Group (2023). Safety and Glycemic Outcomes During the MiniMed TM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics, 25(11), 755-764. https://doi.org/10.1089/dia.2023.0255

Vancouver

Pihoker C, Shulman DI, Forlenza GP, Kaiserman KB, Sherr JL, Thrasher JR, et al. Safety and Glycemic Outcomes During the MiniMed TM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2023;25(11):755-764. doi:10.1089/dia.2023.0255

BibTeX
@article{Pihoker2023,
  author = {Pihoker, Catherine and Shulman, Dorothy I and Forlenza, Gregory P and Kaiserman, Kevin B and Sherr, Jennifer L and Thrasher, James R and Buckingham, Bruce A and Kipnes, Mark S and Bode, Bruce W and Carlson, Anders L and Lee, Scott W and Latif, Kashif and Liljenquist, David R and Slover, Robert H and Dai, Zheng and Niu, Fang and Shin, John and Jonkers, Richard A M and Roy, Anirban and Grosman, Benyamin and Vella, Melissa and Cordero, Toni L and McVean, Jennifer and Rhinehart, Andrew S and Vigersky, Robert A and MiniMed AHCL Study Group, MiniMed AHCL Study Group},
  title = {Safety and Glycemic Outcomes During the MiniMed TM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes},
  journal = {Diabetes Technology & Therapeutics},
  year = {2023},
  volume = {25},
  number = {11},
  pages = {755--764},
  doi = {10.1089/dia.2023.0255}
}
Kostenlos starten →